×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLRX – salarius pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
11:12 am
slrx
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Low
Report
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
12/18
07:50 am
slrx
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Low
Report
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
12/17
04:37 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/17
08:57 am
slrx
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
Medium
Report
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio [Yahoo! Finance]
12/11
04:22 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/5
04:27 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
12/1
08:00 am
slrx
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Medium
Report
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
11/29
03:38 pm
slrx
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
04:38 pm
slrx
Form DEFA14A Salarius Pharmaceuticals
Neutral
Report
Form DEFA14A Salarius Pharmaceuticals
12/19
04:31 pm
slrx
Form 8-K Salarius Pharmaceuticals For: Dec 19
Neutral
Report
Form 8-K Salarius Pharmaceuticals For: Dec 19
11/24
05:08 pm
slrx
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: HANISH ARNOLD C
Medium
Report
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: HANISH ARNOLD C
11/24
11:22 am
slrx
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Marschel Peter Klaus
Low
Report
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Marschel Peter Klaus
11/24
11:22 am
slrx
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Hibner Barbara Louise
Low
Report
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: Hibner Barbara Louise
11/24
11:22 am
slrx
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: PIERCE FREDERICK II
Low
Report
Form 3 Salarius Pharmaceuticals For: Nov 12 Filed by: PIERCE FREDERICK II
11/20
04:42 pm
slrx
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: Rosenblum Mark J
High
Report
Form 4 Salarius Pharmaceuticals For: Nov 20 Filed by: Rosenblum Mark J
11/19
04:05 pm
slrx
Form 8-K Salarius Pharmaceuticals For: Nov 18
Medium
Report
Form 8-K Salarius Pharmaceuticals For: Nov 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Salarius Pharmaceuticals (NASDAQ: SLRX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock.
25.4%
8/26 Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma 21.4%
1/29 Form FWP Salarius Pharmaceuticals Filed by: Salarius Pharmaceuticals, Inc. 20.1%
12/16 Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma 13.4%
3/4 Salarius Announces Allowance of New European Patent Covering Seclidemstat 9.2%
3/25 Form 4 Salarius Pharmaceuticals For: Mar 23 Filed by: McCreedy Bruce J Jr. 7.9%
3/2 Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference 7.8%
2/18 Form 4 Salarius Pharmaceuticals For: Feb 18 Filed by: Jordan Scott 6.6%
2/12 Form 8-K Salarius Pharmaceuticals For: Feb 07 4.7%
11/26 Form 4 Salarius Pharmaceuticals For: Nov 25 Filed by: HANISH ARNOLD C 3.6%
8/26 Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma 21.4%
1/29 Form FWP Salarius Pharmaceuticals Filed by: Salarius Pharmaceuticals, Inc. 20.1%
12/16 Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma 13.4%
3/4 Salarius Announces Allowance of New European Patent Covering Seclidemstat 9.2%
3/25 Form 4 Salarius Pharmaceuticals For: Mar 23 Filed by: McCreedy Bruce J Jr. 7.9%
3/2 Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference 7.8%
2/18 Form 4 Salarius Pharmaceuticals For: Feb 18 Filed by: Jordan Scott 6.6%
2/12 Form 8-K Salarius Pharmaceuticals For: Feb 07 4.7%
11/26 Form 4 Salarius Pharmaceuticals For: Nov 25 Filed by: HANISH ARNOLD C 3.6%
TOP News Decliners
2/7
Form EFFECT Salarius Pharmaceuticals
-58.5%
1/10 Form S-1 Salarius Pharmaceuticals -16.9%
7/29 Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell -16.2%
9/16 Form 8-K Salarius Pharmaceuticals For: Sep 10 -13.6%
9/12 Form 4 Salarius Pharmaceuticals For: Sep 10 Filed by: McVicar William K. -10.8%
1/28 Form S-1/A Salarius Pharmaceuticals -10.6%
2/6 Form S-1/A Salarius Pharmaceuticals -10.4%
7/29 Form SC 13D Salarius Pharmaceuticals Filed by: Sharma Sunil -10.2%
12/17 Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression -9.2%
9/12 Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month -9.1%
1/10 Form S-1 Salarius Pharmaceuticals -16.9%
7/29 Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell -16.2%
9/16 Form 8-K Salarius Pharmaceuticals For: Sep 10 -13.6%
9/12 Form 4 Salarius Pharmaceuticals For: Sep 10 Filed by: McVicar William K. -10.8%
1/28 Form S-1/A Salarius Pharmaceuticals -10.6%
2/6 Form S-1/A Salarius Pharmaceuticals -10.4%
7/29 Form SC 13D Salarius Pharmaceuticals Filed by: Sharma Sunil -10.2%
12/17 Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression -9.2%
9/12 Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month -9.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: